imperial chemical industries is expected to benefit from the results of a cancer study to be published today details of which were revealed yesterday the study carried out by the imperial cancer research fund concludes that women with early breast cancer have a better chance of survival if they take hormonal therapy one of the main forms of hormonal therapy is an oestrogen blocking drug called tamoxifen which is sold by ici under the brand name nolvadex nolvadex launched in 1973 is the largest selling cancer drug in the world with a turnover of between pounds 200m and pounds 250m ici was not prepared to comment on the studys potential impact on profits the research involved 750000 women throughout the world and lasted for five years most uk analysts believed the study would be positive for ici dr jonathan gelles of us securities house wertheim schroder said it will clearly support further growth of this product i would have thought that they should be able to increase unit use by between 20 and 25 per cent